Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4451-4456

  Beuth, J ^a   Ko, H L ^a   Schneider, H ^a   Tawadros, S ^a   Kasper, H U ^b   Zimst, H ^b   Schierholz, J M ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c HELIXOR Heilmittel GmbHandCoKG ^*  (Germany)

Author keywords

Apoptosis; BALB c mice; Cell proliferation; Ductal breast carcinoma; Mistletoe extract; Necrosis

Indexed keywords

KI 67 ANTIGEN; PLANT EXTRACT; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; VISCUM ALBUM EXTRACT A; VISCUM ALBUM EXTRACT M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MITOSIS; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, INBRED BALB C; MISTLETOE; MODELS, ANIMAL; NECROSIS; NEOPLASMS, EXPERIMENTAL; PLANT EXTRACTS;

EID: 33845955943     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kienle GS and Kiene H: Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Schattauer Verlag, Stuttgart, 2003.
2. Beuth J and Moss RW: Complementary oncology. Adjunctive methods in the treatment of cancer. Thieme Int Publ, New York, 2005.
3. Muenstedt K: Ratgeber unkonventionelle Massnahmen. Ecomed Verlag, Landsberg, 2003.
4. Beuth J: Grundlagen der Komplementäronkologie. Theorie und Praxis. Hippokrates Verlag, Stuttgart, 2002.
5. Buessing A: Biological and pharmacological properties of Viscum album L. From tissue flask to men. In: Mistletoe. The Genus Viscum. Buessing A (ed.)., Harwood Academic Publishers, Singapore, pp. 123-182, 2000.
6. Buessing A: Induction of apoptosis by the mistletoe lectins. A review on the mechanisms of cytotoxicity mediated by Viscum album L. Apoptosis 1: 25-32, 1996.
7. Heiny BM and Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342, 1994.
8. Piao BK, Wang YX, Xie GR, Mannsmann U, Matthes H, Beuth J and Lin HS: Impact of complementary mistletoe extract on quality of life in breast, ovarian, non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24: 303-310, 2004.
9. Beuth J, Ko HL, Tunggal L, Buss G, Geisel J, Jeljaszewicz J and Pulverer G: Immunaktive Wirkung von Mistellektin-1 in Abhängigkeit von der Dosierung. Arzneimittelforschung/Drug Res 11: 1255-1258, 1994.
10. Beuth J, Stoffel B, Ko HL, Buss G, Tunggal L and Pulverer G: Immunaktive Wirkung verschiedener Mistellektin-1 Dosierungen in Mammakarzinompatientinnen. Arzneimittelforschung/Drug Res 45: 505-507, 1995.
11. Braun JM, Blackwell CC, Weir DM and Beuth J: Cytokine release of whole blood from adult female donors challenged with mistletoe lectin-1 standardized extract and E. coli endotoxin or phytohaemagglutinin (PHA). Anticancer Res 23: 1349-1352, 2003.
12. Braun JM, Ko HL, Schierholz JM, Weir D, Blackwell CC and Beuth J: Application of standardized mistletoe extracts augment immune response and down regulates metastatic organ colonization in murine models. Cancer Letters 170: 25-31, 2001.
13. Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Moeckel B, Lentzen H and Gerstmayer B: Anticancer activity of r-viscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res 21: 3981-3988, 2001.
14. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W and Mengs U: The standardized mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy. A randomized, placebo-controlled multicenter clinical trial. Anticancer Res 24: 1293-1302, 2004.
15. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J and Beuth J: Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 23: 5081-5088, 2003.
16. Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B: Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Arzneimittelforschung/Drug Res 54: 456-466, 2004.
17. Augustin M, Bock PR, Hanisch J, Karasmann M and Schneider B: Sicherheit und Wirksamkeit der komplementären Langzeitbehandlung von primärem malignem Melanom mit mittlerem bis hohem Risiko (UICC/AJCC-Stadium II und III) mittels fermentiertem Mistelextrakt (Viscum album L.). Arzneimittelforschung/Drug Res 55: 38-49, 2005.
18. Lenartz D, Dott U, Menzel J, Schierholz JM and Beuth J: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20: 2073-2076, 2000.
19. Heiny BM, Albrecht V and Beuth J: Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom. Onkologe 4: 35-39, 1998.
20. Steuer-Vogt M, Bonkovsky V, Ambrosch P, Scholz M, Neiss A, Strutz J, Hennig M, Lenarz T and Arnold W: The effect of adjuvant mistletoe treatment programme in resected head and neck cancer patients. A randomized controlled clinical trial. Eur J Cancer 37: 23-31, 2001.
21. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM, EORTC Melanoma Group in cooperation with the German Cancer Society (DKG): Final results of the EORTC 18871/DKG 80-1 randomized phase III trial. rIFN-gamma versus iscador M versus observation after surgery in melanoma patients with either high risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40: 390-402, 2004.
22. Padura LV and Lloyd RV: Endocrine Pathology. Differential diagnosis and molecular advances. Humana Press, USA, 2004.
23. Aaron AD and Montgomery E: Clinical Pathology of Soft-tissue Tumors. Marcel Dekker Inc., New York, USA, 2001.
24. Staak O, Stoffel B, Wagner H, Pulverer G and Beuth J: In vitro Zytotoxizität der Viscum album Agglutinine I und II. J Oncol 30: 29-33, 1998.
25. Riberau-Gayon G, Jung ML, Franz H and Anton R: Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Anti Cancer Drugs 8: 3-8, 1997.
26. Matthes H, Schad F, Buchwald D and Schenk G: Endoscopic ultra sound-guided fine needle injection of Viscum album L. (mistletoe, helixor M) in the therapy of primary panceas cancer: A pilot study. Gastroenterology 4(S2): 433-434, 2005.
27. Stumpf C, Ramirez-Martinez S, Becher A, Stein GM, Buessing A and Schietzel M: Intratumorale Mistelapplikation bei stenosierendem Rezidiv eines Cardia Carcinoms. Erfahrungsheilkunde 8: 509-513, 1997.
28. Matthes B, Fritz P, Muerdter TE, Kroez M, von Laue H-B and Matther H: Investigation of the immunologic reaction and clinical outcome in intralesional Viscum therapy of coloncarcinoma. In: Scheer R, Bauer R, Becker H et al (eds.), Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. KVC Verlag, Essen, Germany, 2005.
29. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J and Fiebig HH: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 25: 1969-1976, 2005.
30. Lenartz D, Andermahr J, Plum G, Menzel J and Beuth J: Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioblastoma. Anticancer Res 18: 1011-1014, 1998.
31. Burger AM, Mengs U, Keller G, Schulze JB and Fiebig HH: No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res 23: 3801-3806, 2003.
32. Kienle GS, Berrino F, Buessing A, Portalupi E, Rosenzweig S and Kiene H: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8: 109-119, 2003.